Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update on its research and development programs in respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC), and discuss its business outlook for 2019 during Enanta’s presentation at the 37^th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 4:30 p.m. Pacific time.

“Enanta continues to execute on its goals and has never been in a stronger position from both a financial and clinical development perspective,” said Jay R. Luly, Ph.D. President and CEO, Enanta Pharmaceuticals. “Throughout 2019, Enanta has several milestones to look forward to, including Phase 2a clinical datasets from our RSV human challenge study and our Argon-1 NASH study, as well as the first in human study of our lead HBV candidate, EDP-514.”

The following are details of Enanta’s research and development program updates and expectations for 2019.

Research and Development Events Planned for Calendar 2019:

EDP-938, N-Protein Inhibitor for Respiratory Syncytial Virus:

• Dosing is ongoing in a Phase 2a human challenge study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of EDP-938 orally administered to healthy subjects infected with a strain of respiratory syncytial virus. The trial is advancing well, and topline data is now expected mid-2019.

EDP-514, Core Inhibitor for Hepatitis B Virus:

• Pre-clinical data on EDP-514, a promising inhibitor of the HBV core protein, will be presented during the formal presentation on January 7. Data presented on EDP-514 will demonstrate potent inhibition of HBV replication in vitro accompanied by a greater than 4-log viral load reduction in vivo.
• A Phase 1 study of EDP-514, is planned to begin in the second half of 2019. The study will evaluate single and multiple doses of drug in healthy volunteers and will incorporate a Phase 1b arm in patients with chronic HBV infection.

EDP-305, FXR agonist for NASH: